Affluent Medical SA (FR:AFME) has released an update.
Affluent Medical SA has reported significant progress with three clinical programs, secured strategic partnerships including a €15m deal with Edwards Lifesciences, and extended its financial runway to July 2025. The company is advancing in the US market with positive FDA feedback for its KaliosTM mitral ring, and is progressing with patient implants in its Artus urinary sphincter and Epygon mitral valve studies. Moreover, the firm has strengthened its financial position with a €3.5 million capital increase and additional financing from major shareholders.
For further insights into FR:AFME stock, check out TipRanks’ Stock Analysis page.
